Pulse Biosciences, Inc

As of June 30, 2026, Pulse Biosciences, Inc. carries a market capitalization of 1.80B, placing it among publicly traded companies globally. Its enterprise value stands at 1.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Pulse Biosciences, Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Pulse Biosciences, Inc. has 70.80M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1,667.46, and the price-to-book ratio stands at 20.65.

These figures are as of June 30, 2026. The EV/Sales ratio of 1,653.73 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.72B versus a market cap of 1.80B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Pulse Biosciences, Inc. maintains a current ratio of 9.63, meaning it holds 9.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Pulse Biosciences, Inc. posted a negative return on equity (ROE) of -78.49, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -67.90, reflecting losses generated across the asset base. The company generates approximately 9,808.33 in revenue per employee across its workforce of 105.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.24 indicates how many times Pulse Biosciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Pulse Biosciences, Inc.'s stock has gained approximately 190.91% over the past 52 weeks. The 50-day moving average sits at 43.74, while the 200-day moving average is 26.17.

Over the twelve months ended June 30, 2026, Pulse Biosciences, Inc. generated 1.04M in revenue and converted that into -70.07M in net income, yielding earnings per share of -1.03. EBITDA reached -71.79M, while operating income came in at -72.69M.

As of June 30, 2026, Pulse Biosciences, Inc. holds 88.95M in cash and equivalents against 5.93M in total debt, resulting in a net debt position of -88.95M. Total book value stands at 87.09M, with working capital of 82.91M providing operational flexibility.

Pulse Biosciences, Inc. produced -53.48M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -253,837.00 in capital expenditures, free cash flow totaled -53.73M - equivalent to -0.79 per share.

Over the twelve months ended June 30, 2026, Pulse Biosciences, Inc. posted a gross margin of 0.25, reflecting its pricing power and cost economics. The operating margin of -7,007.76 and net profit margin of -6,755.78 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.11: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.76, meaning Pulse Biosciences, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Pulse Biosciences, Inc. has an Altman Z-Score of 69.02, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.